Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients
about
Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitorsInfluence of Preoperative Serum Aspartate Aminotransferase (AST) Level on the Prognosis of Patients with Non-Small Cell Lung Cancer.Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway.Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.The role of 18F-fluorodeoxyglucose uptake of bone marrow on PET/CT in predicting clinical outcomes in non-small cell lung cancer patients treated with chemoradiotherapy.Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients.Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer.Association of serum follistatin levels with histological types and progression of tumor in human lung cancerPrognostic Dynamic Nomogram Integrated with Inflammation-Based Factors for Non-Small Cell Lung Cancer Patients with Chronic Hepatitis B Viral Infection
P2860
Q36540405-14E84860-819C-48CC-9D1A-E2FE93480CAEQ37286453-D3746BB9-91F2-44E1-9EA6-8D883B89790DQ37529089-2F3CF69E-6EB7-4A4A-99DD-496508FDE523Q39281214-F927EAD8-6677-4D53-B2A0-0A9300473DADQ40596565-ED3F6D78-DFFF-4527-BE05-89FA5F062574Q47787176-C5A83C02-6801-4A00-8980-44A2E52261C8Q47821107-5E345B0A-DD31-4E2D-BAF4-AA53969757F9Q49246685-3BD39F8E-A7FE-4734-A9FE-1EE6A8A99962Q58120657-1CCE3516-7009-43A5-9C8B-9482D698BCF7Q59137661-1E25D7C9-7AE7-470C-8527-23B13F4F322A
P2860
Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Pretreatment levels of the ser ...... mall-cell lung cancer patients
@ast
Pretreatment levels of the ser ...... mall-cell lung cancer patients
@en
type
label
Pretreatment levels of the ser ...... mall-cell lung cancer patients
@ast
Pretreatment levels of the ser ...... mall-cell lung cancer patients
@en
prefLabel
Pretreatment levels of the ser ...... mall-cell lung cancer patients
@ast
Pretreatment levels of the ser ...... mall-cell lung cancer patients
@en
P2093
P2860
P1433
P1476
Pretreatment levels of the ser ...... mall-cell lung cancer patients
@en
P2093
Ana Lourdes González-Piñeiro
Elena Yaiza Romero-Ventosa
Francisco Javier Rodríguez-Berrocal
Guadalupe Piñeiro-Corrales
María Páez de la Cadena
Sonia Blanco-Prieto
P2860
P2888
P356
10.1186/S40064-015-0891-0
P577
2015-04-09T00:00:00Z
P5875
P6179
1026755295